The purpose of this Regulation Impact Statement (RIS) is to assist the Australian Government decision making process on how to address problems that have been identified in relation to the labelling of medicines in Australia.
A number of options to address the identified issues are examined in the RIS, including the risk to consumer safety if no action is taken.
These options have been developed following consultation conducted by the Therapeutic Goods Administration (TGA) in 2012, 2014 and 2015. Stakeholders participating in these consultations were industry peak bodies and key health professional and consumer groups including:
Generic Medicines Industry Association (now the Generic and Biosimilar Medicines Association)
Australian Self Medication Industry
Complementary Healthcare Council of Australia (now Complementary Medicines Australia)
The Pharmacy Guild of Australia
Pharmaceutical Society of Australia
Society of Hospital Pharmacists of Australia
Council of Australian Therapeutic Advisory Groups
Australian Medical Association
Royal Australasian College of Physicians
Consumer Health Forum of Australia
A comparison of medicine labelling requirements applied by overseas regulators has also been undertaken. These agencies include Health Canada, the US Food and Drug Administration (FDA), UK Medicines and Healthcare Products Regulatory Agency, European Medicines Agency and New Zealand Medicines and Medical Devices Safety Authority (Medsafe).
The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.